ClinicalTrials.gg
RecruitingNCT07467928Updated Mar 12, 2026

The Long-term Effect of Artificial Intelligence-assisted Colonoscopy on Risk of Metachronous Advanced Colonic Lesion

An interventional study of Suveillance colonoscopy in Colonic Polyps, Artifical Intelligence and Advanced Metachonous Colonic Lesion, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2025, registered Mar 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
404
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this prospective study is to to evaluate the prevalence of metachronous advanced colonic lesions in subsequent surveillance colonoscopies in patients who had previously undergone AI-assisted colonoscopy to conventional colonoscopy examinations.

The main question it aims to answer is whether employing AI-assisted colonoscopy can decrease the likelihood of metachronous advanced colonic lesions during subsequent surveillance colonoscopies.

Researchers will compare patient who undergo conventional colonoscopy in previous colonoscopy to see if AI-assisted colonoscopy can decrease the likelihood of metachronous advanced colonic lesions during subsequent surveillance colonoscopies. Participants will undergo surveillance colonoscopy to assess the presence of metachronous advanced colonic lesion

02

Conditions studied

  • Colonic Polyps
  • Artifical Intelligence
  • Advanced Metachonous Colonic Lesion

Browse trials for

Keywords

  • Colonic polyps
  • Artificial intelligence
  • Surveillance colonoscopy
  • advanced metachonous colonic lesion
03

In context

Colonic Polyps

377 studies on the registry are indexed under Colonic Polyps; 57 are open to participants now.

This study's planned enrollment of 404 is above the median of 274 across 250 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,292 studies on the registry; 348 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants are those who were previously enrolled and completed our randomized controlled trial comparing AI-assisted and conventional colonoscopy

Exclusion criteria

Exclusion Criteria:

  • In addition to the baseline exclusion criteria of the index trial, patients who were found to have inflammatory bowel disease, colorectal cancer and underwent bowel resection would be excluded. Similar to index trial, patients who have developed severe comorbid illnesses that make surveillance colonoscopy and polypectomy unsafe, or become unable to provide for trial participation would also be excluded

Index trial: Lui TK, Lam CP, To EW, Ko MK, Tsui VWM, Liu KS, et al. Endocuff With or Without Artificial Intelligence-Assisted Colonoscopy in Detection of Colorectal Adenoma: A Randomized Colonoscopy Trial. Am J Gastroenterol. 2024;119(7):1318-25

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
404 participants (estimated)

Study arms

  • Other
    Surveillance colonoscopy

    Surveillance colonoscopy

    Procedure: Suveillance colonoscopy

Interventions

  • ProcedureSuveillance colonoscopy

    Surveillance colonoscopy

06

What researchers measure

Primary outcomes

  1. the cumulative risk of metachronous advanced colonic lesions

    the cumulative risk of metachronous advanced colonic lesions

    Time frame: Three years

Secondary outcomes

  1. cumulative risk of non-advanced metachronous adenoma and serrated lesions

    cumulative risk of non-advanced metachronous adenoma and serrated lesions

    Time frame: three years

  2. mean number of metachronous advanced colonic lesions

    mean number of metachronous advanced colonic lesions

    Time frame: three years

  3. mean number of metachronous adenomas, advanced adenomas, serrated lesions, and advanced serrated lesions

    mean number of metachronous advanced colonic lesions, adenomas, advanced adenomas, serrated lesions, and advanced serrated lesions

    Time frame: three years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It would require the approval of local authority

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467928
Responsible party
Dr. Lui Ka-Luen (Clinical Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Mar 12, 2026
Start date
Jul 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Mar 12, 2026

Study contacts

Thomas KL Clinical Assoicate Professor, MD
Contact
tkllui@hku.kh
852 + 97360997

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion